Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextrothyroxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 11/20 | 0.74 |
| ▸ | THRA known ✓ | P10827 | 7/20 | 0.74 |
| ▸ | USP2 | O75604 | 4/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | PPARG | P37231 | 5/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | TTR | P02766 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | RXRA | P19793 | 2/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrothyroxine SCHEMBL7112166 | 1.00 | USP2 (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL2327406 | 1.00 | USP2 (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL5498887 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL34102 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL582058 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL1995243 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Levothyroxine SCHEMBL1560691 | 0.94 | THRB (0.86) | USP2L3MBTL1THRBMEN1KMT2A | |
| Levothyroxine SCHEMBL4965467 | 0.94 | THRB (0.86) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL15569465 | 0.91 | THRB (0.91) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL4437395 | 0.87 | THRB (0.61) | USP2L3MBTL1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526701-B2 | Sustained drug release and improved product stability using non-covalent particle coating methods | JEROME STEVENS PHARMACEUTICALS, INC. | 2016-12-27 | — | — | US | claimed |
| WO-2009136249-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM WITH REDUCED LEVELS OF IMPURITIES | CADILA PHARMACEUTICALS LTD. (IN) | 2009-11-12 | — | — | WO | claimed |
| US-12636270-B2 | Levothyroxine liquid formulations | FRESENIUS KABI USA, LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-20240382441-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | FRESENIUS KABI USA, LLC (US) | 2024-11-21 | — | — | US | disclosed |
| US-12043590-B2 | Co-crystals comprising levothyroxine and a dicarboxylic acid | SANDOZ AG (CH) | 2024-07-23 | — | — | US | disclosed |
| CN-117919171-B | Preparation method of levothyroxine sodium oral liquid | 泊诺(天津)创新医药研究有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117919171-A | Preparation method of levothyroxine sodium oral liquid | 泊诺(天津)创新医药研究有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117624330-A | T4-BSA coated antigen and preparation method thereof | 郑州伊美诺生物技术有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-3884280-B1 | METHODS AND KITS FOR DETECTING LIVER DYSFUNCTION IN A SUBJECT | INST NAT SANTE RECH MED (FR) | 2024-01-17 | — | — | EP | disclosed |
| US-11298331-B2 | Solid pharmaceutical preparation containing levothyroxine | MERCK PATENT GMBH (DE) | 2022-04-12 | — | — | US | disclosed |
| US-20220096414-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | FRESENIUS KABI USA, LLC (US) | 2022-03-31 | — | — | US | disclosed |
| EP-1346722-A1 | METHOD FOR PRODUCING PREPARATION CONTAINING BIOACTIVE SUBSTANCE | Takeda Chemical Industries, Ltd. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-20030148936-A1 | Bioactive peptides | ALPHARMA AS. | 2003-08-07 | — | — | US | disclosed |
| US-20030022821-A1 | Bioactive peptides | ALPHARMA AS | 2003-01-30 | — | — | US | disclosed |
| EP-1263471-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066147-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2001-09-13 | — | — | WO | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382441-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | TPO, SSTR5, TSHR | THRB 14/4885THRA 11/4885USP2 4235/4885 |
| US-12636270-B2 | Levothyroxine liquid formulations | TPO, SSTR5, TRHDE | THRB 12/4885THRA 13/4885USP2 3146/4885 |
| US-20220096414-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | TPO, SSTR5, TSHR | THRB 14/4885THRA 11/4885USP2 4235/4885 |
| US-12043590-B2 | Co-crystals comprising levothyroxine and a dicarboxylic acid | TPO, OTC, THRA | THRB 18/4885THRA 3/4885USP2 3080/4885 |
| US-20030148936-A1 | Bioactive peptides | VIP, NGLY1, HM13 | THRB 1859/4885THRA 1996/4885USP2 4109/4885 |
| US-20030022821-A1 | Bioactive peptides | VIP, LITAF, LNPEP | THRB 1687/4885THRA 1983/4885USP2 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.